Metformin promotes placental adaptation to hypoxic stress through mitochondrial and translational pathways
- 1Department of Obstetrics, Gynaecology and Newborn Health, University of Melbourne, Mercy Hospital for Women, 163 Studley Rd, Heidelberg, 3084 Australia
- 2ACRF Centre for Imaging the Tumour Environment, Olivia Newton John Cancer Centre, 145 Studley Road, Heidelberg, 3084 Australia
- 3School of Cancer Medicine, La Trobe University, Melbourne, VIC 3086 Australia
Abstract
Background: Preeclampsia is a leading cause of maternal and perinatal morbidity worldwide, with no approved disease-modifying medical therapy. The disorder originates from placental insufficiency characterised by chronic hypoxia, oxidative stress, inflammation, and mitochondrial dysfunction within placental trophoblasts. Although metformin is widely used in pregnancy and has shown benefit in preeclampsia clinical trials, its mechanism of action including direct effects on placental protein synthesis and mitochondrial adaptation under hypoxic conditions remain poorly defined. Our aim was to determine how metformin modulates placental protein synthesis and mitochondrial function under physiological and hypoxic conditions relevant to placental dysfunction.
Methods: Primary human placental trophoblasts were cultured under normoxic (8% O₂) or hypoxic (1% O₂) conditions and treated with metformin. Label-free quantitative proteomics was used to identify altered molecular pathways. Mitochondrial adaptation was assessed by analysis of mitochondrial dynamics markers, electron transport chain (ETC) complex expression, and reactive oxygen species (ROS) production.
Results: Metformin upregulated proteins involved in RNA processing, protein synthesis, and metabolism, while downregulating proteins associated with extracellular matrix organization and apoptosis. Under hypoxic conditions, metformin increased markers of mitochondrial fission and significantly upregulated ETC complexes I, II, and IV. These changes were associated with reduced cellular ROS levels. Importantly, enhanced protein synthesis occurred without activation of unfolded protein response pathways, indicating preservation of cellular homeostasis.
Conclusion: Metformin enhances placental adaptation to hypoxic stress by coordinating protein synthesis and mitochondrial respiratory function while reducing oxidative stress. These mechanistic findings provide translational insight into how metformin may improve placental resilience and support its further evaluation as a therapeutic strategy for preeclampsia and other pregnancy complications driven by placental dysfunction.
Trial registration: Not applicable. This study does not meet the NHMRC definition of a clinical trial.
Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s12967-026-08798-4.
Related
- Cell type-specific placental signatures in polyendocrine metabolic ovary syndrome and metformin
- Effect of metformin treatment on brain 18F-FDG uptake: a translational study
- Placental alkaline phosphatase promotes lipid accumulation and fibrosis in ligamentum flavum hypertrophy and represents a potential target for statin repurposing
- Metformin promotes apoptosis of senescent chondrocytes by disrupting the Bcl-xL/Mcl-1–Bak interaction
- Current Translational 3D In Vitro Models of Human Placental Tissue
BibTeX
@article{kadife2026metformin,
title = {{Metformin promotes placental adaptation to hypoxic stress through mitochondrial and translational pathways}},
author = {Elif Kadife and Alesia Harper and Ishara Atukorala and Sarah Ellis and Fiona C. Brownfoot},
journal = {Journal of Translational Medicine},
year = {2026},
month = aug,
doi = {10.1186/s12967-026-08798-4},
url = {https://doi.org/10.1186/s12967-026-08798-4},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Metformin promotes placental adaptation to hypoxic stress through mitochondrial and translational pathways
AU - Elif Kadife
AU - Alesia Harper
AU - Ishara Atukorala
AU - Sarah Ellis
AU - Fiona C. Brownfoot
PY - 2026
DA - 2026/08/17
JO - Journal of Translational Medicine
DO - 10.1186/s12967-026-08798-4
UR - https://doi.org/10.1186/s12967-026-08798-4
AB - Background: Preeclampsia is a leading cause of maternal and perinatal morbidity worldwide, with no approved disease-modifying medical therapy. The disorder originates from placental insufficiency characterised by chronic hypoxia, oxidative stress, inflammation, and mitochondrial dysfunction within placental trophoblasts. Although metformin is widely used in pregnancy and has shown benefit in preeclampsia clinical trials, its mechanism of action including direct effects on placental protein synthesis and mitochondrial adaptation under hypoxic conditions remain poorly defined. Our aim was to determine how metformin modulates placental protein synthesis and mitochondrial function under physiological and hypoxic conditions relevant to placental dysfunction. Methods: Primary human placental trophoblasts were cultured under normoxic (8% O₂) or hypoxic (1% O₂) conditions and treated with metformin. Label-free quantitative proteomics was used to identify altered molecular pathways. Mitochondrial adaptation was assessed by analysis of mitochondrial dynamics markers, electron transport chain (ETC) complex expression, and reactive oxygen species (ROS) production. Results: Metformin upregulated proteins involved in RNA processing, protein synthesis, and metabolism, while downregulating proteins associated with extracellular matrix organization and apoptosis. Under hypoxic conditions, metformin increased markers of mitochondrial fission and significantly upregulated ETC complexes I, II, and IV. These changes were associated with reduced cellular ROS levels. Importantly, enhanced protein synthesis occurred without activation of unfolded protein response pathways, indicating preservation of cellular homeostasis. Conclusion: Metformin enhances placental adaptation to hypoxic stress by coordinating protein synthesis and mitochondrial respiratory function while reducing oxidative stress. These mechanistic findings provide translational insight into how metformin may improve placental resilience and support its further evaluation as a therapeutic strategy for preeclampsia and other pregnancy complications driven by placental dysfunction. Trial registration: Not applicable. This study does not meet the NHMRC definition of a clinical trial. Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s12967-026-08798-4.
SN - 1479-5876
ER -